Medical Management of Small bowel Crohn s Disease: An evidence-based approach
|
|
- Hector Lucas
- 5 years ago
- Views:
Transcription
1 Medical Management of Small bowel Crohn s Disease: An evidence-based approach E. Jan Irvine, M.D., F.R.C.P.(C)., M.Sc. Professor of Medicine, University of Toronto, Head, Division of Gastroenterology, St. Michael s Hospital, Toronto Ontario, Canada
2 Learning objectives After this presentation participants will be able to: Understand the goals of therapy for Crohn s disease Identify the most effective evidence-based therapies for active small bowel Crohn s disease and maintenance of remission
3 Goals of Therapy Induce and maintain remission Steroid sparing Heal mucosa Minimize disease and treatment toxicity Optimize quality of life (Select optimal timing for surgery)
4 General Considerations Crohn s disease diagnosis (history, physical exam, stools, serology) Extent, location, behavior (inflammatory, stricturing, penetrating) Imaging- endoscopic, radiologic Disease severity Stool frequency, rectal bleeding, pain, weight loss, extraintestinal, Blood work: CBC, CRP, albumin, B12. Response to therapy Drug, dosage, duration
5 Targets for Anti-inflammatory Therapy Luminal bacteria (antibiotics, probiotics) T-cell activation (immunomodulators) Cytokine modulation Signal transduction T-cell and helper subsets Adhesion molecules and leukocyte recruitment Non-specific mediators of injury and repair
6 Mild/Moderate and Moderate/Severe* Ambulatory Eating without: Dehydration Toxicity Abdominal tenderness Pain or mass Obstruction >10% weight loss Stool frequency, bleeding Assess well-being, social function. Not responding to Rx Or with more prominent Fever Weight loss Abdominal pain/tenderness Nausea/vomiting (nonobstructve) Anemia *Symptoms on steroids with Obstruction Rebound Cachexia abscess Hanauer SB, Sandborn W. Am J Gastroenterol 2001;96:637
7 Crohn s disease-step-up therapy Active CIR Budesonide Prednisone 6-mercaptopurine or azathioprine (methotrexate) Infliximab Remission 5-ASA? Post operative prevention only 13% benefit CIR budesonide 6Mercaptopurine/Azathioprine or methotrexate Infliximab
8 Sulfasalazine in active CD Modest benefit at best Active colonic, ileocolonic 1g/15kg up to 5g/d given for at least 12 weeks National Cooperative Crohn s Study - 17wks) Placebo 30% remission p<.05 SASP 43% remission Benefit 13% NNT=8 Primary effect in colonic disease; predictors of no benefit: prior steroid use and small bowel involvement Summers RW et al. Gastroenterol 1979:77:847-69
9 Pentasa in active Crohn s disease: Meta-analysis 5-ASA in doses < 3g/d are not effective for active Crohn s disease Akobeng AK, Garderer E. Cochrane Database Syst Rev Jan 25;(1):CD Pentasa 4g/day and placebo (619 pts) Ileocecal pts had decrease of 63 points in CDAI for Pentasa vs. 45 for placebo (delta of 18) Is this a clinically important benefit? Hanauer S:B et al. Clin Gastroenterol Hepatol 2004;2:379-88
10 Toxicity Sulphasalazine (10-45%) Headache, nausea, epigastric pain, diarrhea, (reduced sperm count & motility) Idiosyncratic (3%) Stevens-Johnson syndrome, pancreatitis, agranulocytosis, or alveolitis Mesalamine (15%) Diarrhoea (3%), headache (2%), nausea (2%), and rash (1%) are reported Renal disease (interstitial nephritis), pancreatitis significantly more common with mesalamine Carter MJ et al. Gut 2004; 53:v1-v16
11 Budesonide vs. Placebo in Active CD P < NNT = 4 % Remissio placebo budesonide 10 0 Greenberg 1994 Tremaine 2002 Greenberg GR et al New Engl J Med 1994;331:836 Tremaine WJ et al. Amer J Gastroenterol 2002;97:1748
12 Budesonide in active CD Superior to placebo (2 studies): ABI 23% NNT = 4 Superior to 5-ASA (1 study): ABI 26% NNT = 4 Conventional CS superior (5 studies) Similar benefit low activity group (data not given for high activity group) Adverse events reduced in budesonide ARR 21% NNT = 5 (heterogeneity present; serious ADE not separated) Kane, S. V et al. Alimentary Pharmacology & Therapeutics, 2002; 16:1509 Recent randomized trial lesser bone loss at 2yrs budesonide vs. prednisolone (1% vs. 3.8%) steroid naïve patients only Schoon EJ et al. Clin Gastroenterol Hepatol 2005;3:
13 Corticosteroids in active CD Suppresses IL transcription, arachidonic acid metabolism, induces stability NFΚB complex, and apoptosis of lymphocytes (lamina propria). Author Duration (wks) Dose (mg pred/kg/d) N Rem n Placebo CS OR NNT Summers Malchow Modigliani
14 Corticosteroid toxicity Early supraphysiological doses» cosmetic (acne, moon face, oedema)» sleep and mood disturbance» dyspepsia» glucose intolerance. Prolonged (>12 weeks)» posterior subcapsular cataracts, osteoporosis, osteonecrosis femoral head, myopathy, and susceptibility to infection. Long-term withdrawal» adrenal insufficiency» myalgia, malaise, and arthralgia» raised intracranial pressure. Carter MJ et al. Gut 2004; 53:v1-v16
15 Azathioprine and 6MP in acute CD 9 trials OR Active 3.09 (95% CI, 2.45 to 3.91) After 17 wks OR increased NNT = 3-6 Steroid sparing effect: NNT = 3 Pearson DC et al. Ann Int Med 1995;122:132 Sandborn WJ et al. Cochrane Database Syst Rev. 2000;(2):CD
16 Methotrexate: Evidence from single RCT MTX 25 mg i.m. weekly Limited efficacy active disease; Meta-analysis: Significant heterogeneity of 5 published trials 50 Remission % 25 P = Placebo Methotrexate 25 mg/wk 0 All patients >20mg/d <20 mg/d Treatment group Feagan BG et al. New ENgl J Med 1995;332:292 Alfadhli AA et al. Cochrane Database Syst Rev Jan 25;(1):CD003459
17 Infliximab: the CA2 Trial: Clinical response and remission in patients with active Crohn s disease P< Response (%) % 64% 4% P= % Placebo N = 25 Infliximab 5, 10 and 20mg/kg N= week clinical response 4 week clinical remission Targan SR et al. New Eng J Med 1997;337:1029
18 Drug Toxicity Toxicity of Infliximab Lymphoma, infusion reactions, delayed hypersensitivity, severe infections (TB assessment CXR, TB skin test) Methotrexate CBC, LFT s monthly, liver biopsy if high risk, pneumonitis, hepatotoxicity AZA/6MP CBC, LFT s monthly, metabolites-if available, for hepatotoxicity Pancreatitis, rash, opportunistic infection, lymphoma
19 Evidence-based algorithm for small bowel CD Pentasa (?clinical significance of benefit) Budesonide (ileocecal CD) mild/moderate Conventional corticosteroids administered for 8 16 wk more severe Relapse 6 12 months another cycle of induction therapy; maintenance azathioprine, 6- mercaptopurine, or methotrexate) budesonide 6mg od. alternative to immunosuppressive or for prednisone-dependent patients. Sandborn WJ. Am J Gastroenterol (12 Suppl):S1-5. Hanauer SB, Stromberg U. Clin Gastroenterol Hepatol. 2004;2: Sandborn, WJ, Feagan BG Aliment Pharmacol Ther. 2003;18:263-77
20 Number needed to treat active small bowel CD Active Infliximab 3 Corticosteroids 2/3 Budesonide 4 (ileocecal) Azathioprine 7 (steroid sparing) 3 Methotrexate 5 (steroid dep t)
21 Crohn s Remission Maintenance 5-ASA marginal benefit (13%) in post-operative but not medically treated patients Camma C et al. Gastroenterol 1997;113:1465 Corticosteroids Not conventional (high ADE) Budesonide 6mg/d for steroid dependent pts Mantzaris et al Clin Gastro Hepatol2003;1:122; Cortot A ET al. Gut MP/AZA Benchmark Rx Relapse 21% 18mons vs. 8% continued if remission for 42 mons pre-randomization Lemann M et al;. Gastroenterol 2002
22 Crohn s Remission Maintenance Metronidazole 20mg/kg/d for 3 mons Significant at 3 mons but not 1-3yrs, high ADE Rutgeerts P et al, Gatroenterol Methotrexate 15 mg s.c. weekly for 40 wks 65% vs. 39% placebo. Infliximab Feagan B et al. NEJM 2000 ca2 Trial Rutgeerts et al ACCENT I Plac. 21%, 5mg 39%, 10mg 45% (every 8 weeks) Shorten interval, increase dose to improve efficacy. Hanauer SB et allancet 2002
23 Azathioprine and 6MP in remission CD 5 trials of 319 patients: one yr. remission 67% for AZA vs. 52% for placebo OR Quiescent disease 2.27 (CI, 1.76 to 2.93) NNT = 7 Pearson DC et al. Ann Int Med 1995;122:132 Sandborn WJ et al. Cochrane Database Syst Rev. 2000;(2):CD
24 Methotrexate for remission maintenance N = 76; 15mg; i.m. weekly % P = placebo methotrexate 0 remission Feagan B et al. New Engl J Med 2000;342: 1627
25 Maintenance IFX Therapy: ACCENT I Trial Multicenter RDBPCT (45 centers in NA, Europe, Israel; N = 573; CDAI >220, all given IFX 5mg/kg, responders randomized 3 groups for 46wk Infliximab 5mg/kg Responders only 335 pts (58%)responded Placebo wks 2, 6 and Q8wks, N=110 Infliximab 5mg/kg wks 2,6,Q8wks, N=113 Infliximab 5mg/kg wks 2,6; 10mg/kg Q8wks, N=112 Group I Group II Group III Hanauer SB et al. Lancet 2002;359:1541
26 Results week 54 Accent I 60 P =.002 P < % P = P=.244 Group I Group II Group III 10 P =.003 P= Remission Response Hanauer SB et al. Lancet 2002;359:1541
27 Infliximab - Infusion Reactions Acute: adverse reaction during or within 24 hrs of initial or subsequent infusions Delayed: adverse reaction from 24 hrs to 14 days after re-treatment Loss of responsiveness Symptoms: Arthralgia Myalgia Urticarial rash Fever Malaise Management: Acetominophen Antihistamines Steroids (200 mg i.v.)
28 Infliximab Guidelines (CAG) Induction: wk 0 5mg/kg (or 3 dose induction 0/2/6 augments response 15%) If inadequate response 2 nd dose 2weeks If inadequate response (consider 10mg/kg) Repeat dosing Q8weeks 5mg/kg Recommended concomitant immunosuppressives Guidelines for prevention of infusion reaction Panaccione R et al. Can J Gastroenterol 2004;18:503
29 Extensive small bowel disease No RCT specific data Systemic cortcosteroids Early immunomodulation (azathioprine or 6MP[methotrexate]) Steroid dependent or refractory proceed to immunomodulators Infliximab ECCO Consensus Travis SP et al. Gut 2006;55Suppl1:i16-35
30 Fistulizing Crohn s Disease IFX for fistulae-94 pts with abdominal or perianal fistulae RCT 68% 5mg/kg vs. 56% 10,g/kg vs. 26% placebo P<.02 50% decrease number of draining fistulae Present D et al. New Engl J Med. 1999;340:1398 ACCENT II IFX for maintenance of fistulizing disease 195/306 (0/2/6) responders at week 10/14 randomized Time to loss of response 40wks (IFX5mg/kg 8weekly) vs. 14 weeks (placebo) P<.001) Wk 54 36% IFX complete closure vs. 19% placebo P =.009 Sands B et al. New Engl J Med 2004;350:876 Tacrolimus for fistulae 10 week RCT.2mg/kg/d 43% decrease 50% vs. 8% (p=.004) 10% vs. 8% for remission (p=.86) Sandborn WJ et al. Gastroenterol 2003;125:380
31 Stricturing small bowel Crohn s disease Anecdotal evidence dilatation of short strictures (<4cm) Accessible by endoscopy using TTS balloon dilatation Multiple sessions Risks: bleeding, perforation (1% to 4%) Multiple, proximal resection, stricuturoplasty Risks: short bowel Low fiber diet, intermittent antibiotics
32 The ideal management of CD: Top down vs. step-up? Top Down = IFX 5mg/kg 0-2-6/AZA 2.5mg/kg (rescue:ifx &/or MTX) Step Up = pred 40/8wk taper (rescue repeat CS then AZA then IFX) P=.006 P < % Top down Step-up Success Steroids MTX/AZA/6MP Hommes D et al. DDW 2005/Gastroenterol in press
33 Summary: medical therapy for small bowel CD Acute and chronic Budesonide 9mg/d mild/mod ileocecal disease 6mg for maintenance in some patients Prednisone 40-60mg/d mod/severe; i.v. steroids No role in maintenance Add AZA/6MP or methotrexate for early relapse or steroid dependence Use infliximab if steroid resistant, only partial response for induction, or fistulizing Reserve infliximab maintenance for AZA/6MP/MTX allergic or unresponsive Surgery
34 Promising therapies not yet approved or in trials Trichuris suis-phase III?Natalizumab (SAM) PML toxicity 3 deaths MLN-02, LDP-02 Adalimumab CDP870 MRA Sargramostim (GMCSF) Filgrastim Probiotics (VSL-3) Stem-cell transplantation Leukophoresis Antibiotics Somatropin (human growth hormone) CNI-1493 (MAP-K inhibitors)
35 Acute therapy of Crohn s Disease Amino-salicylates Induction of remission mild only Prevention post-operative Antibiotics or budesonide Induction of remission in CD Corticosteroids Induction moderate and severe Crohn s disease Ineffective maintenance Immunomodulators Induction moderate and severe Effective maintenance Biologicals Induction and maintenance Perianal Other
36 Crohn s disease monitoring (endpoints for RCT) CDAI (Crohn s disease activity index) (<150) #stools, abdominal pain, well being, need for antidiarrheal, abdominal mass, Hct, body weight, extra-gi symptoms Best WR et al Gastroenterol 1976; 70:439; Gastroenterol 1979;77:843. CDEIS (Crohn s disease endoscopic index severity) Stenosis, deep ulceration, superficial ulceration and % affected Mary JY, Modigliani R. Gut 1989;30:983; D Haens G et al. Histological Severity Damage (epithelium, architecture), inflammation (l.p.-mono/pmn; epithelium-pmn), eriosion/ulcer; granuloma; % affected. Geboes K et al. Gut 2000;7:404 Perianal Disease Activity Pain, discharge, restricted sex, induration, worst finding. Irvine EJ. J Clin Gastroentetrol 1995;20:27 Laboratory parameters C-reactive protein (ESR); fecal calprotectin; other. Vermeire S et al. Inflamm Bowel Dis ;10: Roseth A et al. Digestion 197;58:176 HRQOL Generic (e.g. SF-36, PQWB), Disease specific (IBDQ) Ware, J. Med Care 1992;30:473 Guyatt G et al, Gastroenterol 1989;96:804
37 Treatments that are not recommended or are in effective in active small bowel CD 5-ASA <3g/d for acute CD; or for remission maintenance Antibiotics Cyclosporine IL-10 Alicaforsen (anti-icam1) Etanercept, onercept
38 Chronic active (steroid refractory, dependent) Steroid-refractory: active disease despite adequate dose and duration of prednisolone (> 20 mg/d for 2 weeks). Steroid dependent: relapse when steroid reduced below 20 mg/day, or within 6 weeks of stopping or requiring >10mg for 4/12 previous months.
39 6-MP Metabolism 6-TU 6-TG nucleotides DNA RNA AZA XO 6-MP HPRT 6-TIMP TPMT 6-MMP Circulation TPMT 6-MMP ribonucleotides Intracellular Purine synthesis
40 Grading Evidence and Recommendations Ia - From meta-analysis of RCTs Ib - From >1 RCT IIa - Well-designed, controlled non-randomized study IIb Well-designed experimental study design IIIa Non-experimental design IV - Expert opinion, descriptive, anecdotal evidence A = Recommendation based on Evidence Ia or Ib B = Recommendation based on Evidence IIa, IIb or III C = Recommendation based on Evidence IV
41 Step-up vs. step-down treatment (small bowel) Infliximab Azathioprine Corticosteroids Budesonide 5-Aminosalicylates or no treatment
Efficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationHow to use infliximab?
How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationTherapy for Inflammatory Bowel Disease
Therapy for Inflammatory Bowel Disease Jonathan P. Terdiman, MD Professor of Clinical Medicine Clinical Director, Center for Colitis and Crohn s Disease University of California San Francisco, CA UC: Current
More informationTreatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG
Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationUlcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13
Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationSlide 1 Medications in inflammatory bowel disease a primer for health care providers. Slide 2. Slide 3 Theory of pathogenesis. IBD - epidemiology
Slide 1 Medications in inflammatory bowel disease a primer for health care providers Athos Bousvaros, MD Associate director Inflammatory Bowel Disease Center Boston Children s Hospital 617 355 2962 Slide
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationINFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL
INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL A. Hillary Steinhart, MD MSc FRCP(C) Medical Lead, Mount Sinai Hospital IBD Centre Professor of Medicine University
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationTumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review)
Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review) Behm BW, Bickston SJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationFistulizing Crohn s Disease: The Aggressive Approach
Fistulizing Crohn s Disease: The Aggressive Approach Bruce E. Sands, MD, MS MGH Crohn s and Colitis Center and Gastrointestinal Unit Massachusetts General Hospital Boston, USA Case Presentation: Summary
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationOptimizing Immunomodulators and
Optimizing Immunomodulators and Biologics i in Inflammatory Bowel Disease Sunanda Kane, MD, MSPH, FACG Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota,
More informationAchieving Success in Ulcerative Colitis: the Role of Infliximab
Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationEmerging Therapies in IBD 2006
Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationUntil the late 1990s, treatment of Crohn s disease was primarily aimed at
CHALLENGES IN CROHN S DISEASE An Historical Overview of the Treatment of Crohn s Disease: Why Do We Need Biological Therapies? Paul J. Rutgeerts, MD, PhD, FRCP Faculty of Medicine, Gastroenterology Section,
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationIBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital
IBD Case Studies David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Sunanda Kane, MD, FACG Professor of Medicine Department of Gastroenterology and Hepatology Mayo Clinic Rochester, MN In my lecture today, I will be
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationOnce Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis
Once Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University JKM 2014 Svartz N. Acta Med Scand
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationMild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France
Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested Philippe Marteau, Paris, France Sequential vs combined treatments When should one switch? Sequential vs combined treatments
More informationOf Treatment For Inflammatory Bowel Diseases
Balancing The Risks And Benefits Of Treatment For Inflammatory Bowel Diseases Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical School Director, Inflammatory Bowel Diseases Center Dartmouth-Hitchcock
More informationCrohn s Disease: A New Approach to an Old Problem
Management of Postoperative Crohn s Disease: A New Approach to an Old Problem Miguel Regueiro, M.D. Associate Professor of Medicine Associate Chief for Education Clinical Head and Co-Director, IBD Center
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More information5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease
5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease David T. Rubin, MD Associate Professor of Medicine Co-Director, Inflammatory Bowel Disease Center University it of Chicago Medical
More informationLatest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D.
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Co-Director, IBD Center Director, Nutrition Support Service UPMC Presbyterian Hospital Division of Gastroenterology,
More informationCROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
More informationU of Cape Town, South Africa, 10 U of Washington, Seattle, WA,USA, 11 CHRU de Lille, Hôpital Claude Huriez, Lille, France, 12
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Ustekinumab, a Human IL-12/23p40 Monoclonal Antibody, in Moderate-severe Crohn s Disease Refractory to Anti-TNFα: UNITI-1 WJ Sandborn 1,
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationPD Dr. med. R. Wiest / Dr. med. P. Juillerat, MSc. Donnerstag 18 ten Oktober 2012 UPDATE PROKTOLOGIE: Konservative Behandlungsmöglichkeiten?
PD Dr. med. R. Wiest / Dr. med. P. Juillerat, MSc Donnerstag 18 ten Oktober 2012 UPDATE PROKTOLOGIE: Fisteln bei M. Crohn : Konservative Behandlungsmöglichkeiten? INTERDISZIPLINÄRE VISZERALE CHIRURGIE
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More informationPreventing post-operative recurrence
Oxford Inflammatory Bowel Disease MasterClass Preventing post-operative recurrence Dr Oliver Brain Oxford Disclosures Presented at IEE, Oxford 2013 AbbVie sponsored meeting Talk Outline Risk factors for
More informationReview article: medical treatment of mild to moderately active Crohn s disease
Aliment Pharmacol Ther 2003; 17 (Suppl. 2): 18 22. Review article: medical treatment of mild to moderately active Crohn s disease R. LÖFBERG Karolinska Institutet, IBD-unit at HMQ Sophia Hospital, Stockholm,
More informationAnti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis
Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis University, 1st Department of Medicine Budapest June 13-15,
More informationManagement of the Hospitalized IBD Patient. Drew DuPont MD
Management of the Hospitalized IBD Patient Drew DuPont MD Ulcerative Colitis: Indications for Admission Severe ulcerative colitis Frequent loose bloody stools ( 6 per day) Severe cramps Systemic toxicity:
More informationRisk = probability x consequence
Explaining Risks of IBD Therapy to Parents and Patients December 4, 2009 CCFA Advances in IBD Hollywood, FL Corey A. Siegel Assistant Professor of Medicine, Dartmouth Medical School Director, Dartmouth-Hitchcock
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationImproving outcome of Inflammatory Bowel Disease in children
Improving outcome of Inflammatory Bowel Disease in children Dinesh Pashankar, MD Pediatric Gastroenterologist Director- Pediatric IBD program Yale University School of Medicine Pediatric Gastroenterology
More informationCrohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine
Crohn's disease Crohn's disease is an inflammatory condition of the digestive tract that affects children and adults. Common features of Crohn's disease include mouth sores, diarrhea, abdominal pain, weight
More informationAlthough no existing pharmacologic agent
MEDICAL THERAPY OF CROHN S DISEASE: A REVIEW OF RECENT INNOVATIONS Bruce E. Sands, MD, MS* ABSTRACT Crohn s disease (CD) affects approximately 500 000 Americans, usually striking between the ages of 15
More informationPerianal Fistula of Crohn s Disease
Case 3 Perianal Fistula of Crohn s Disease A 16 year-old boy referred by surgeon due to perianal fistula since 6mo ago CC=perianal pain History of intermittent non-bloody diarrhea and mild abdominal pain
More informationCrohn s
Crohn s Disease David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology, and Nutrition Co-Director, Digestive Diseases Center @IBDMD Disclosures
More informationPercent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =
Fistulizing Crohn s Disease Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology & Hepatology Mayo Clinic Rochester, Minnesota, USA Outline Fistulizing Crohn s Etiology Incidence
More informationMy Child Has Inflammatory Bowel Disease : Why? What now? What s next?
My Child Has Inflammatory Bowel Disease : Why? What now? What s next? George M. Zacur, M.D., M.S. Clinical Assistant Professor Department of Pediatrics and Communicable Diseases Division of Gastroenterology
More informationINFLAMMATORY BOWEL DISEASE
1. Medical Condition INFLAMMATORY BOWEL DISEASE (IBD) specifically includes Crohn s disease (CD) and ulcerative colitis (UC) but also includes IBD unclassified (IBDu), seen in about 10% of cases. These
More informationAnti tumor necrosis factor (TNF) agents have
Achieving Clinical Response and Remission in Moderate-to-Severe Ulcerative Colitis With Golimumab Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: May 1, 2018 Last Revised: April 18, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationBEYOND MOLECULAR BIOLOGY: IMPROVING QUALITY OF LIFE IN PATIENTS WITH CROHN S DISEASE. Stephen B. Hanauer, MD*
BEYOND MOLECULAR BIOLOGY: IMPROVING QUALITY OF LIFE IN PATIENTS WITH CROHN S DISEASE Stephen B. Hanauer, MD* ABSTRACT *Professor of Medicine and Clinical Pharmacology; Chief, Section of Gastroenterology,
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: June 9, 2019* Last Revised: Feb. 12, 2019 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationOPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG
1C: Advances in Inflammatory Bowel Disease OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG narrow interpretation of this presentation topic would A be a discussion of dosing
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationTreatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
Alimentary Pharmacology and Therapeutics Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort N. Gies, K. I. Kroeker, K. Wong & R. N. Fedorak Division
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationDr David Epstein Vincent Pallotti Hospital and University of Cape Town
Inflammatory Bowel Disease Management in South Africa in 2016 Pharmaceutical Care Management Association Dr David Epstein Vincent Pallotti Hospital and University of Cape Town Inflammatory Bowel Disease
More information